

WOMEN LIVING WITH HIV

While HIV can affect everyone differently, women may face particular challenges. Understanding the relationship of being a woman living with HIV and your current HIV treatment regimen may have implications on your decisions now and in the future.^{1,2}

THESE ARE A FEW QUESTIONS YOU CAN ASK AT YOUR NEXT VISIT TO HELP YOU AND YOUR DOCTOR MAKE A SUITABLE DECISION FOR YOU.



Patient portrayal

LIVING WITH HIV AS A WOMAN

- How does HIV affect my reproductive health?
- What birth control options are available for HIV+ women? Does birth control interact with my HIV medications?
- Does my HIV treatment affect my menstruation?
- How can I protect my partner from the risk of HIV transmission?

HIV AND PREGNANCY/BREASTFEEDING

- What is the risk of HIV transmission to my baby during labour?

- Does being pregnant make my HIV worse?
- Is my current treatment the recommended option for women who wish to become pregnant?
- Should HIV medicines be continued during pregnancy and/or breastfeeding?
- Can I breastfeed my baby?

HIV AND MENOPAUSE

- Does HIV or HIV treatment affect menopause?
- Are there any considerations during menopause for women living with HIV?

TICK OFF THE QUESTIONS THAT ARE IMPORTANT TO YOU

ASK YOUR DOCTOR IF DOVATO IS RIGHT FOR YOU

Scan the QR code to learn more and access useful resources available on WWW.DOVATO.CO.NZ



Patient portrayal

Please consult with your doctor or pharmacist before taking DOVATO. Because DOVATO does not cure HIV infection, patients on DOVATO may still develop other infections and illnesses linked to HIV infection. Side effects people may experience are headache, nausea, and diarrhoea.³

Abbreviations: HIV, human immunodeficiency virus; HIV+, HIV positive; NZ, New Zealand

References: 1. HIV.gov. HIV Basics, HIV and women's health issues. Updated Feb 27th 2026. Available from: www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/womens-health-issues/ (accessed Feb 2026). 2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV (updated Sept 2025). 3. GlaxoSmithKline NZ, DOVATO Consumer Medicine Information. 2025. Available at: <https://www.medsafe.govt.nz/consumers/cmi/d/dovato.pdf> (accessed Feb 2026).

Dovato is a film coated tablet containing 50 mg of dolutegravir (as dolutegravir sodium) and 300 mg of lamivudine, which is used for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component. **Dovato is a Prescription Medicine. Dovato has risks and benefits and should be initiated by a doctor experienced in treating HIV. Dovato is a funded medicine; Special Authority criteria apply. Ask your doctor if Dovato is right for you.** Use strictly as directed. If you have concerns, or side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's consultation fees apply. For more information, you can view the Dovato Consumer Medicine Information at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. Marketed on behalf of ViiV Healthcare by GlaxoSmithKline NZ Limited, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.** Date of Approval: **May 2026** | Date of Expiry: **May 2028** | TAPS-NP24718 | PM-NZ-DLL-PINF-260003

This material is intended for NZ audiences only. Any information provided on this document should be discussed with a healthcare professional and does not replace a healthcare professional's advice.